Broad and Enabling IP Estate

MDRNA is the single company with the breadth of intellectual property to enable RNAi based therapeutic approaches to all human diseases utilizing both multiple siRNA constructs and multiple delivery technologies. We have an intellectual property estate that:

• Covers UsiRNA and meroduplex siRNA
• Protects siRNA sequences against 140 validated human disease gene targets
• Protects a novel combinatorial, alkylated amino acid library in a liposome delivery platform
• Covers RNA-peptide conjugates
• Protects a library of novel delivery peptides

The Company has in-licensed key patent rights including the seminal Fire & Mello patents which permit the use of double stranded RNA to induce the RNA interference pathway for therapeutic uses. MDRNA acquired intellectual property related to non-nucleotide monomer (UNA) chemistry technology which permits MDRNA to stabilize and provide drug-like properties to UsiRNAs in a novel and proprietary manner. MDRNA has built a significant patent portfolio based on internal innovation which includes one issued patent, 27 U.S. applications and 93 PCT applications covering siRNA constructs, chemistry, delivery, gene targets and target families, and therapeutic indications.